Wall Street Zen Upgrades Structure Therapeutics to Hold Rating

Structure Therapeutics (NASDAQ: GPCR) received a notable upgrade from Wall Street Zen, which changed its rating from “sell” to “hold” in a report released on November 6, 2023. This adjustment comes amid a series of mixed analyses from various financial institutions regarding the company’s stock performance.

Analyst Ratings and Price Targets

Other analysts have weighed in on Structure Therapeutics with differing perspectives. On November 28, HC Wainwright reaffirmed a “buy” rating and established a target price of $60.00 for the shares. Similarly, Morgan Stanley increased its price target for the company from $120.00 to $125.00, assigning the stock an “overweight” rating.

Stifel Nicolaus also showed optimism by raising its price objective from $50.00 to $90.00 and giving a “buy” rating. In contrast, Zacks Research lowered its rating from “hold” to “strong sell” on October 17. Lifesci Capital recently upgraded the shares to a “strong buy” rating as of September 8.

In total, one analyst has rated Structure Therapeutics with a “strong buy,” eleven have issued “buy” ratings, and two have given it a “sell.” As per data from MarketBeat, the stock currently holds an average rating of “moderate buy” with an average target price of $95.78.

Earnings Report and Institutional Investment

Structure Therapeutics reported its quarterly earnings on November 6, revealing earnings per share of ($0.37). This figure fell short of the consensus estimate of ($0.36) by $0.01. Analysts anticipate that the company will post earnings of ($0.82) per share for the current fiscal year.

Recent activity among institutional investors indicates a growing interest in Structure Therapeutics. The State of Wyoming acquired a new stake in the company during the second quarter, valued at approximately $28,000. Additionally, EverSource Wealth Advisors LLC increased its position by an impressive 530.0% during the third quarter, now holding 1,071 shares valued at $30,000.

National Bank of Canada FI expanded its holdings by 1,448.2% in the first quarter, now owning 2,957 shares worth $51,000. Assetmark Inc. boosted its stake by 39.9% in the second quarter, bringing its total to 2,877 shares valued at $60,000. PNC Financial Services Group Inc. also increased its position by 29.1%, now holding 4,415 shares worth $92,000.

Currently, approximately 91.78% of Structure Therapeutics’ stock is owned by hedge funds and institutional investors, reflecting significant confidence in the company’s potential.

About Structure Therapeutics

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical firm focused on developing innovative oral therapeutics to address various chronic diseases with unmet medical needs. Its lead product candidate, GSBR-1290, is an oral small molecule that acts as a biased agonist of the glucagon-like peptide-1 receptor, targeting key pathways for treating type-2 diabetes mellitus and obesity.

As the company navigates evolving market conditions and analyst ratings, its performance will be closely watched by investors and stakeholders alike.